Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

mTOR Signaling and Cancer Progression

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...

PI3K/mTOR/AKT Signaling Pathway

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a rapamycin-insensitive companion...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Leniolisib reduced lymphoproliferative disease in murine autoimmune lymphoproliferative syndrome.

Journal of human immunity·2026

Same author

Clinical characteristics, management, and hematopoietic cell transplantation of patients with TLR8 gain-of-function.

Blood advances·2025

Same author

Impact of Anti-CD4 Autoantibodies on Immune Reconstitution in People With Advanced HIV.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·2024

Same author

PI3Kγ in B cells promotes antibody responses and generation of antibody-secreting cells.

Nature immunology·2024

Same author

Long-term treatment with selective PI3Kδ inhibitor leniolisib in adults with activated PI3Kδ syndrome.

Blood advances·2024

Same author

Author Correction: GIMAP5 deficiency reveals a mammalian ceramide-driven longevity assurance pathway.

Nature immunology·2024

Search research articles

Related Experiment Video

Updated: Jun 7, 2026

Spatio-Temporal Manipulation of Small GTPase Activity at Subcellular Level and on Timescale of Seconds in Living Cells

Spatio-Temporal Manipulation of Small GTPase Activity at Subcellular Level and on Timescale of Seconds in Living Cells

Published on: March 9, 2012

Serendipity in splendid isolation: rapamycin.

¹NATIONAL INSTITUTES OF HEALTH.

|January 9, 2016

Summary

Rapamycin therapy shows significant efficacy in treating refractory cytopenias, particularly in children with autoimmune lymphoproliferative syndrome (ALPS). This long-term, single-agent treatment offers a promising option for these challenging hematologic conditions.

Area of Science:

Hematology
Immunology
Pediatric Oncology

Background:

Refractory cytopenias represent a significant challenge in hematology, often lacking effective long-term treatment options.
Autoimmune lymphoproliferative syndrome (ALPS) is a rare genetic disorder characterized by immune dysregulation and cytopenias.
Current therapeutic strategies for refractory cytopenias and ALPS have limitations, necessitating novel treatment approaches.

Purpose of the Study:

To evaluate the efficacy and safety of long-term, single-agent rapamycin therapy in patients with refractory cytopenias.
To specifically assess the impact of rapamycin in pediatric patients diagnosed with autoimmune lymphoproliferative syndrome (ALPS).
To establish rapamycin as a potential therapeutic agent for challenging hematologic conditions.

Main Methods:

More Related Videos

A Semi-Quantitative Drug Affinity Responsive Target Stability (DARTS) assay for studying Rapamycin/mTOR interaction

A Semi-Quantitative Drug Affinity Responsive Target Stability (DARTS) assay for studying Rapamycin/mTOR interaction

Published on: August 27, 2019

Development and Application of Rapamycin-regulated Tyrosine Phosphatases

Development and Application of Rapamycin-regulated Tyrosine Phosphatases

Published on: September 6, 2024

Related Experiment Videos

Last Updated: Jun 7, 2026

Spatio-Temporal Manipulation of Small GTPase Activity at Subcellular Level and on Timescale of Seconds in Living Cells

Spatio-Temporal Manipulation of Small GTPase Activity at Subcellular Level and on Timescale of Seconds in Living Cells

Published on: March 9, 2012

A Semi-Quantitative Drug Affinity Responsive Target Stability (DARTS) assay for studying Rapamycin/mTOR interaction

A Semi-Quantitative Drug Affinity Responsive Target Stability (DARTS) assay for studying Rapamycin/mTOR interaction

Published on: August 27, 2019

Development and Application of Rapamycin-regulated Tyrosine Phosphatases

Development and Application of Rapamycin-regulated Tyrosine Phosphatases

Published on: September 6, 2024

Conducted the first prospective, multi-institutional clinical trial involving 30 patients.
Administered rapamycin as a long-term, single-agent therapy.
Monitored patient outcomes, focusing on hematologic parameters and clinical response.

Main Results:

Rapamycin demonstrated remarkable efficacy in treating refractory cytopenias.
Significant improvements were observed in children with autoimmune lymphoproliferative syndrome (ALPS).
The long-term, single-agent approach proved effective in a challenging patient cohort.

Conclusions:

Long-term rapamycin therapy is a highly effective treatment for refractory cytopenias.
Rapamycin offers a promising therapeutic option for pediatric patients with autoimmune lymphoproliferative syndrome (ALPS).
This study supports the use of rapamycin in managing complex hematologic disorders.